|
|
.
|
Abdollah
F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio
N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.
Survival
following biochemical recurrence after radical prostatectomy and
adjuvant radiotherapy in patients with prostate cancer: the impact
of competing causes of mortality and patient stratification.
Eur
Urol. 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006.
Epub 2013 Mar 13.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Brockman
JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW,
Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW,
Stephenson AJ.
Nomogram
Predicting Prostate Cancer-specific Mortality for Men with
Biochemical Recurrence After Radical Prostatectomy.
Eur
Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019.
Epub 2014 Oct 6.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Dell'Oglio
P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini
M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.
Predicting
survival of men with recurrent prostate cancer after radical
prostatectomy.
Eur
J Cancer. 2016 Feb;54:27-34. doi: 10.1016/j.ejca.2015.11.004. Epub
2015 Dec 19.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Jeffers
A, Sochat V, Kattan MW, Yu C, Melcon E, Yamoah K, Rebbeck TR,
Whittemore AS.
Predicting
Prostate Cancer Recurrence After Radical Prostatectomy.
Prostate.
2016 Oct 24. doi: 10.1002/pros.23268. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Lee
BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW,
Stephenson AJ.
Are
biochemical recurrence outcomes similar after radical
prostatectomy and radiation therapy? Analysis of prostate
cancer-specific mortality by nomogram-predicted risks of
biochemical recurrence.
Eur
Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017.
Epub 2014 Oct 5.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Lu
K.
Re:
Byron H. Lee, Adam S. Kibel, Jay P. Ciezki, et al. Are biochemical
recurrence outcomes similar after radical prostatectomy and
radiation therapy? Analysis of prostate cancer-specific mortality
by nomogram-predicted risks of biochemical recurrence. Eur Urol
2015;67:204-9.
Eur
Urol. 2015 Sep;68(3):e61-2. doi: 10.1016/j.eururo.2015.04.015.
Epub 2015 Apr 22.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Mithal
P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK,
Amling CL, Freedland SJ.
Prostate-specific
antigen level, stage or Gleason score: which is best for
predicting outcomes after radical prostatectomy, and does it vary
by the outcome being measured? Results from Shared Equal Access
Regional Cancer Hospital database.
Int
J Urol. 2015 Apr;22(4):362-6. doi: 10.1111/iju.12704. Epub 2015
Feb 24.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Phillips
R.
Prostate
cancer: treatment-specific nomograms, biochemical recurrence, and
prostate cancer-specific mortality.
Nat
Rev Urol. 2014 Dec;11(12):657. doi: 10.1038/nrurol.2014.294. Epub
2014 Oct 21.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Porter
CR, Suardi N, Capitanio U, Hutterer GC, Kodama K, Gibbons RP,
Correa R Jr, Perrotte P, Montorsi F, Karakiewicz PI.
A
nomogram predicting prostate cancer-specific mortality after
radical prostatectomy.
Urol
Int. 2010;84(2):132-40. doi: 10.1159/000277588. Epub 2010 Mar 4.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Simon
RM, Salama JK, Freedland SJ.
Radical
prostatectomy versus radiation therapy: can pretreatment nomograms
be used to select the appropriate prostate cancer treatment?
Eur
Urol. 2015 Feb;67(2):210-1. doi: 10.1016/j.eururo.2014.10.009.
Epub 2014 Oct 28.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Teeter
AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL,
Freedland SJ.
Do
nomograms designed to predict biochemical recurrence (BCR) do a
better job of predicting more clinically relevant prostate cancer
outcomes than BCR? A report from the SEARCH database group.
Urology.
2013 Jul;82(1):53-8. doi: 10.1016/j.urology.2012.10.090.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Uchio
EM, Aslan M, Wells CK, Calderone J, Concato J.
Impact
of biochemical recurrence in prostate cancer among US
veterans.
Arch
Intern Med. 2010 Aug 9;170(15):1390-5. doi:
10.1001/archinternmed.2010.262.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Unwala
DJ.
Editorial
comment.
Comment
on “Do
nomograms designed to predict biochemical recurrence (BCR) do a
better job of predicting more clinically relevant prostate cancer
outcomes than BCR? A report from the SEARCH database group.
[Urology. 2013]”
Urology.
2013 Jul;82(1):58-9; discussion 59. doi:
10.1016/j.urology.2012.10.093.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zattoni
F, Agostini E, Cattaneo F, Maruzzo M, Basso U, Zattoni F,
Evangelista L.
Fluorocholine
PET/CT predicts skeletal progression, skeletal event and cancer
specific survival in patients with biochemical relapse for
prostate cancer.
Clin
Imaging. 2017 Feb 24;43:110-116. doi:
10.1016/j.clinimag.2017.02.003. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
CLINICAL
ENDPOINTS FOR HIGH-RISK PROSTATE CANCER
|
|
.
|
Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero
P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone
V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M,
Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate
Cancer Clinical and Translational Research group (EMPaCT).
Defining the Most Informative Intermediate Clinical
Endpoints for Predicting Overall Survival in Patients Treated with
Radical Prostatectomy for High-risk Prostate Cancer.
Eur
Urol Oncol. 2019 Jul;2(4):456-463. doi: 10.1016/j.euo.2018.12.002.
Epub 2018 Dec 24.
Source
|
Abstract
|
Similar
articles
|
|
|
PROSTATE-SPECIFIC
ANTIGEN DOUBLING TIME
|
|
.
|
Freedland
SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC,
Partin AW.
Death
in patients with recurrent prostate cancer after radical
prostatectomy: prostate-specific antigen doubling time subgroups
and their associated contributions to all-cause mortality.
J
Clin Oncol. 2007 May 1;25(13):1765-71. DOI:
10.1200/JCO.2006.08.0572
Source
| Full
text |
Similar
articles
|
|
|
Observation
after BCR without salvage therapy or delayed administration is a
viable option for low-risk patients with a Gleason score ≤ 7
and PSADT ≥ 6 months.
|
|
***
|
Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Tanaka N, Takeda T,
Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M.
Type
of patients in whom biochemical recurrence after radical
prostatectomy can be observed without salvage therapy.
World
J Urol. 2019 Sep 26. doi: 10.1007/s00345-019-02970-w. [Epub ahead
of print]
Source
.
Similar
articles
|
|
|
|
|
|
|
